Journal article
Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke
Journal of stroke and cerebrovascular diseases, Vol.22(2), pp.100-106
02/2013
DOI: 10.1016/j.jstrokecerebrovasdis.2011.06.017
PMCID: PMC5619691
PMID: 21835634
Abstract
The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known. Our objective was to determine if aspirin treatment failure predicts recurrent ischemic stroke and/or death.
We performed a post-hoc analysis of data from the National Institute of Neurological Disorders and Stroke (NINDS) intravenous recombinant tissue plasminogen activator (rt-PA) trial and the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Multivariate analysis was used to calculate the odds ratio (OR) of recurrent stroke and recurrent stroke or death for aspirin treatment failure patients for the duration of available follow-up (3 months for TOAST patients; 12 months for NINDS rt-PA trial patients).
The rate of aspirin treatment failure was 40% and 35% among 1275 patients and 624 patients recruited in the TOAST and NINDS rt-PA trials, respectively. The risk of stroke and death at 3 months and 1 year was not higher among patients classified as aspirin treatment failures among the TOAST (OR 1.1; 95% confidence interval [CI] 0.8-1.6; P = .7) or NINDS rt-PA trial patients (OR 0.8; 95% CI 0.6-1.3; P = .4), respectively. In subgroup analysis, aspirin treatment failure was not found to be associated with recurrent stroke or with the combined endpoint of stroke and death among categories defined by etiologic subtype, including those with large artery atherosclerosis.
In a post-hoc analysis of 2 randomized ischemic stroke trials, aspirin treatment failure was not found to be associated with an increased risk of recurrent stroke or death.
Details
- Title: Subtitle
- Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke
- Creators
- Alexandros L Georgiadis - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaSteve M Cordina - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaGabriela Vazquez - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaNauman Tariq - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaM. Fareed K Suri - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaKamakshi Lakshminarayan - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, MinnesotaHarold P Adams - Department of Neurology, University of Iowa, Iowa City, IowaAdnan I Qureshi - Zeenat Qureshi Stroke Research Center, Department of Neurology, University of Minnesota, Minneapolis, Minnesota
- Resource Type
- Journal article
- Publication Details
- Journal of stroke and cerebrovascular diseases, Vol.22(2), pp.100-106
- DOI
- 10.1016/j.jstrokecerebrovasdis.2011.06.017
- PMID
- 21835634
- PMCID
- PMC5619691
- NLM abbreviation
- J Stroke Cerebrovasc Dis
- ISSN
- 1052-3057
- eISSN
- 1532-8511
- Publisher
- Elsevier Inc
- Grant note
- Minnesota Medical Foundation 0840053N / American Heart Association Established Investigator Award K23NS051377 / National Institutes of Health U58DP000857 / Centers for Disease Control and Prevention #84500-2002 / American Academy of Neurology fellowship NMT Medical, Schering-Plough, Medtronic, and Merck RO-1-NS44976-01A2 / National Institutes of Health
- Language
- English
- Date published
- 02/2013
- Academic Unit
- Neurology; Iowa Neuroscience Institute
- Record Identifier
- 9984020893302771
Metrics
38 Record Views